Last update Jan. 30, 2021

Ipratropium Bromide

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Short-acting anticholinergic, specific antagonist of muscarinic receptors, which inhibits the bronchoconstrictive effects of acetylcholine.
Indicated in the treatment of asthma.
Inhaled administration.

At latest update no published data on excretion into breastmilk were found.

Because of a large volume of distribution along with a very low or undetectable plasma concentration reached after inhalation (Boehringer 2015, AEMPS 2013, Laurikainen 1988, Wood 1995), it must be very unlikely the passage of significant amounts into breastmilk.
Its low oral bioavailability would hamper the pass to the infant’s plasma through the breastmilk ingested (AEMPS 2013).

It has been used to treat newborns (Pediamecum 2015).

Experts and scientific societies consider the use of ipratropium bromide during breastfeeding as devoid of risk to the infant (Hale, Lactmed, Amir 2011, National Asthma Education 2004, van Haren 1998).


  • Albuterol ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Ipratropium Bromide in other languages or writings:


Main tradenames from several countries containing Ipratropium Bromide in its composition:


Variable Value Unit
Oral Bioavail. 2 (inhal: 7 - 28) %
Molecular weight 430 daltons
Protein Binding < 10 %
VD 2.4 l/Kg
pKa 15.15 -
Tmax 1 - 2 hours
1.6 hours


  1. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from Consulted on April 10, 2024 Full text (link to original source)
  2. LactMed. Drugs and Lactation Database (LactMed). Internet. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: 2006 - Consulted on March 15, 2022 Full text (link to original source)
  3. Comité de Medicamentos de la Asociación Española de Pediatría. Bromuro de ipratropio. Pediamécum. 2015 Full text (in our servers)
  4. Boehringer. Ipratropium. Drug Summary. 2015 Full text (in our servers)
  5. AEMPS. Ipratropio. Ficha técnica. 2013 Full text (in our servers)
  6. Amir LH, Pirotta MV, Raval M. Breastfeeding--evidence based guidelines for the use of medicines. Aust Fam Physician. 2011 Sep;40(9):684-90. Review. Abstract Full text (link to original source) Full text (in our servers)
  7. National Asthma Education and Prevention Program Asthma and Pregnancy Working Group. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update. 2004;1-57. None 2004 Full text (link to original source) Full text (in our servers)
  8. Nice FJ, De Eugenio D, Dimino TA, Freeny IC, Rovnack MB, Gromelski JS. Medications and Breast-Feeding: A Guide for Pharmacists, Pharmacy Technicians, and Other Healthcare Professionals. Part I. J Pharm Technol 2004;20:17-27. doi: 10.1177/875512250402000106.
  9. H Abdine F Belal H, A Al-Badr A. Ipratropium bromide: drug metabolism and pharmacokinetics. Profiles Drug Subst Excip Relat Methodol. 2003 Abstract
  10. van Haren EH, Devies IE, Mol MJ, Koudijs JW. [Asthma and pregnancy]. Ned Tijdschr Geneeskd. 1998 Abstract
  11. Wood CC, Fireman P, Grossman J, Wecker M, MacGregor T. Product characteristics and pharmacokinetics of intranasal ipratropium bromide. J Allergy Clin Immunol. 1995 Abstract
  12. Ensing K, de Zeeuw RA, Nossent GD, Koëter GH, Cornelissen PJ. Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. Eur J Clin Pharmacol. 1989 Abstract
  13. Laurikainen E, Koulu M, Kaila T, Scheinin M, Isalo E. Evaluation of the systemic anticholinergic activity of nasally administered ipratropium bromide. Rhinology. 1988 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM